Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice by Agustín-Pavón, C et al.
RESEARCH ARTICLE Open Access
Deimmunization for gene therapy: host
matching of synthetic zinc finger constructs
enables long-term mutant Huntingtin
repression in mice
Carmen Agustín-Pavón1,4†, Michal Mielcarek1†, Mireia Garriga-Canut2,3 and Mark Isalan1*
Abstract
Background: Synthetic zinc finger (ZF) proteins can be targeted to desired DNA sequences and are useful tools for gene
therapy. We recently developed a ZF transcription repressor (ZF-KOX1) able to bind to expanded DNA CAG-repeats in the
huntingtin (HTT) gene, which are found in Huntington’s disease (HD). This ZF acutely repressed mutant HTT expression in
a mouse model of HD and delayed neurological symptoms (clasping) for up to 3 weeks. In the present work, we sought
to develop a long-term single-injection gene therapy approach in the brain.
Method: Since non-self proteins can elicit immune and inflammatory responses, we designed a host-matched analogue
of ZF-KOX1 (called mZF-KRAB), to treat mice more safely in combination with rAAV vector delivery. We also tested a
neuron-specific enolase promoter (pNSE), which has been reported as enabling long-term transgene expression, to see
whether HTT repression could be observed for up to 6 months after AAV injection in the brain.
Results: After rAAV vector delivery, we found that non-self proteins induce significant inflammatory responses in the
brain, in agreement with previous studies. Specifically, microglial cells were activated at 4 and 6 weeks after treatment
with non-host-matched ZF-KOX1 or GFP, respectively, and this was accompanied by a moderate neuronal loss. In
contrast, the host-matched mZF-KRAB did not provoke these effects. Nonetheless, we found that using a pCAG promoter
(CMV early enhancer element and the chicken β-actin promoter) led to a strong reduction in ZF expression by 6 weeks
after injection. We therefore tested a new non-viral promoter to see whether the host-adapted ZF expression could be
sustained for a longer time. Vectorising mZF-KRAB with a promoter-enhancer from neuron-specific enolase (Eno2, rat)
resulted in up to 77 % repression of mutant HTT in whole brain, 3 weeks after bilateral intraventricular injection of 1010
virions. Importantly, repressions of 48 % and 23 % were still detected after 12 and 24 weeks, respectively, indicating that
longer term effects are possible.
Conclusion: Host-adapted ZF-AAV constructs displayed a reduced toxicity and a non-viral pNSE promoter improved
long-term ZF protein expression and target gene repression. The optimized constructs presented here have potential for
treating HD.
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Background
The development of increasingly safe gene therapy vec-
tors, with reduced immunogenicity [1], low insertional
capabilities [2], and new and more effective delivery
strategies [3, 4], has led to several successful clinical tri-
als. Examples include a therapy against metachromatic
leukodystrophy (inserting the functional enzyme arylsul-
fatase A in hematopoietic cells) [5], and a breakthrough
in AIDS treatment that promises a 'functional cure' for
HIV [6]. In particular, the latter study employed the
technology of synthetic zinc finger nucleases [7], tar-
geted to knock-out the CCR5 receptor in CD4 T cells,
ex vivo. Nuclease-modified cells were autologously trans-
planted back into patients, achieving drug-free reduction
of viraemia. Site-specific nuclease technology is highly
scaleable and, with the advent of vectorisable RNA-
programmable nucleases such as CRISPR/Cas9 lentivi-
ruses [8], a revolution in genome editing is underway.
Despite this progress, it is becoming clear that the host
immune system is a major barrier to successful long
term therapies. In some cases, including the examples
above, cells can be treated ex vivo, or with a single short
intervention. However, in many diseases it is necessary
to modify the expression of disease genes in vivo. The
superbly versatile CRISPR/Cas systems face an issue
here, because of their bacterial origins: their immuno-
genicity limits their use in repetitive or sustained dosage
regimes. Even zinc finger nucleases use bacterial nucle-
ase domains (FokI [9]) and it is unclear how they would
be tolerated in vivo.
Immunological effects are particularly relevant when
considering gene therapies for neurodegenerative diseases.
Most neurodegenerative diseases require the correction of
mutation(s) in vivo, directly in the affected tissue, or the
sustained expression of therapeutic factors [10]. Since the
brain has limited regenerative capacity, and complex con-
nectivity, the tissue cannot simply be removed, repaired
and re-implanted. Furthermore, a collection of recent arti-
cles has demonstrated delayed immune responses when
injecting foreign proteins from AAV vectors into the brain
parenchyma [11-13]. Strikingly, despite the immune-
privileged environment of the brain, even GFP can induce
a strong inflammatory and immune response in both rats
and monkeys [11, 12]. Similarly, a human enzyme with
potential use in Parkinson’s disease therapy has unwanted
effects in rats [11]. Using the vector AAV9, which is
capable of infecting both neurons and glial cells, neuronal
death starts as early as 3 weeks after injection. Therefore,
even though a range of new generation synthetic biology
tools are being developed for degenerative diseases [10], the
brain still remains a challenging target for gene therapy.
We recently developed a zinc finger-based gene ther-
apy approach to target the fatal monogenic neurodegen-
erative disorder Huntington's disease (HD). To be
successful, this project requires tackling the problems of
sustained transgene expression in the brain [14]. In HD,
the huntingtin (HTT) gene is expanded in a region con-
taining repeats of the glutamine-encoding DNA triplet,
CAG. This results in expanded poly(CAG) transcripts
and polyglutamine (polyQ) proteins, which are both
cytotoxic [15]. Neurodegeneration occurs in several
motor-related areas of the brain, leading to symptoms
that include psychiatric disturbances, chorea, and even-
tually fatality. Nine human genes contain potential
CAG-expansion regions and every one is associated with
a polyQ disease [16]. The available pharmacological
interventions only alleviate symptoms, without stopping
disease progression, and so new treatments are desper-
ately required.
Several new therapeutic approaches in animal models
of HD are beginning to show impressive results, espe-
cially using antisense oligonucleotides [17, 18]. These
approaches allow the regulation of the gene product,
but cannot correct the mutation or stop transcription.
Unfortunately, in vivo mutation correction - using
genome-editing tools directly in the brain - is not
easily achievable. We found that zinc finger nucleases
do not cleave poly(CAG) DNA efficiently even in
vitro, presumably because the highly repetitive DNA
prevents correct nuclease dimerization. By contrast,
we showed that long-chain zinc fingers, fused to a
KRAB transcription repression domain, were a feas-
ible alternative [14]. Since its discovery [19], the hu-
man KRAB domain from KOX1 (ZNF10) has proved
to be an efficient repressor of target genes, when
fused to heterologous DNA-binding domains [20].
KOX1 recruits cellular factors that lay down hetero-
chromatin and thus cause strong long-term and
long-range gene repression across a genomic locus
[21].
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Taking this KRAB-repressor approach, and aiming
for a treatment that could potentially be used to treat
all the nine polyQ diseases, we designed a synthetic
ZF-KOX1 fusion to bind expanded CAG repeats se-
lectively [14]. We showed that intracerebral adminis-
tration of ZF-KOX1, in recombinant adeno-associated
vectors (pseudotype rAAV2/1), was able to acutely re-
duce the load of mutant huntingtin (mut HTT) RNA,
and HTT protein, in the striata of R6/2 mice. The
reduction was greatest at 2 weeks after treatment and
was paralleled by a delay in the onset of clasping be-
haviour (a sign of neurological degeneration). These
results demonstrated that synthetic transcription
factors are therapeutically active after viral delivery in
the brain.
In the current study, we aimed to test the conse-
quences of expressing a synthetic zinc finger peptide
in the brain over a longer period, to check for inflam-
matory and innate immune responses against non-
host proteins. In particular, although the zinc finger
scaffold we used is based on the mouse Zif268 pro-
tein [22], the DNA-recognition helices were not
originally designed to minimise the number of foreign
(non-mouse) peptide sequences, and these are poten-
tially antigenic. Moreover, the human KOX1 (ZNF10)
gene does not have an exact mouse homolog. Conse-
quently, to avoid possible immune rejection in the
mouse, we designed a new mouse host-matched ZF
(mZF) that aimed to minimise the number of foreign
peptide sequences that might form epitopes. For ex-
ample, we replaced KOX1 with a KRAB domain from
the mouse Zfp87 gene (also called Mzf22 [23]) to
make mouse host-adapted mZF-KRAB. We injected
ZF-KOX1, mZF-KRAB or GFP into the brains of
mice and evaluated inflammatory responses and neur-
onal loss, initially up to 6 weeks after treatment,
while comparing mut HTT repression efficiency. We
chose this time point because it precedes full symp-
tom development in our mouse model, thus minimiz-
ing animal suffering, while still allowing time for
inflammatory responses to develop: previously re-
ported results showed that inflammatory responses
were well developed five weeks post-injection of
AAV in rats [11]. Having evaluated these responses,
we went on to test our new lead construct, mZF-
KRAB, with a different, non-viral promoter from
neuron-specific enolase (Eno2, rat). The aim was to
see whether we could achieve repression of the mu-
tant HTT allele over a longer time period. Specific-
ally, we aimed to verify whether there was
measurable repression in the whole brain for at least
6 months after AAV injection. Thus, we aimed to
develop the basis for a single-injection, long-term
gene therapy for HD.
Methods
Design of the host-adapted ZF
Full sequences are available in Additional file 1. We
converted ZF-KOX1 into a more mouse-compatible
version, mZF-KRAB, as follows: (1) We removed the
triple FLAG-tag reporter from ZF-KOX1. (2) We re-
placed the viral SV40 nuclear localization signal
(NLS) with a mouse primase p58 NLS (RIRKKLR;
GenBank: BAA04203.1), using native adjacent residues
as linkers. (3) We employed a zinc finger framework
that was as close as possible to the mouse Zif268
sequence [22], while retaining functional CAG-
binding residues on the DNA recognition helices.
Thus, the QRATLQR helix was changed to QSGDLTR
or QSGDRKR (differences to wild-type mouse protein
sequence vary from finger-to-finger within the Zif268
scaffold; Fig. 1a). Previous phage ELISA experiments
[24], guided our helix design to bind CAG triplets.
(4) We modified the ZF linkers to make them as
close as possible to canonical ZF linkers (e.g., TGEKP,
TGQKP), while retaining non-wild-type longer spacers
(TGSQKP) after every 2 fingers; these spacers are
essential for long ZF arrays to function [25]. Longer
linkers after Fingers F5 and F11 were also slightly
shortened (see Additional file 1). (5) We replaced hu-
man KOX1 with the mouse KRAB repression domain
from Zfp87 (a.k.a. Mzf22 [23]; refSeq_NM_133228.3).
This domain was chosen because the 1-76 amino acid
KRAB-domain fragment of Zfp87, when fused to Gal4
DNA-binding domain, has been reported to have similar
levels of repression compared to Gal4-KOX1 [23].
Mice
For this study we used R6/1, R6/2 and wild type (WT)
mice. R6/2 transgenic mice were purchased form
Jackson Laboratories (B6CBA-Tg(HDexon1)62Gpb/3 J).
Ovarian transplanted hemizygous females and WT
B6CBAF1/J males were bred in house, and progeny was
genotyped as previously described [26]. R6/1 transgenic
mice (B6.Cg-Tg(HDexon1)61Gpb/J) and WT controls
(C57BL/6 J) were purchased form Jackson Laboratories.
For the testing of mZF-KRAB, we decided to switch
from R6/2 to R6/1 to avoid early onset of symptoms and
to comply with animal welfare conditions in the UK,
since the aim of this study was not to check for a pheno-
type reversal. Stereotaxic injections were performed on
4-week-old R6/2 mice, 8-week-old R6/1 mice and 4- to
8-week-old WT mice. All animal experiments were con-
ducted in accordance with Directive 86/609/EU of the
European Commission, the Animals (Scientific Proce-
dures) 1986 Act of the United Kingdom, and following
protocols approved by the Ethical Committee of the
Barcelona Biomedical Research Park and the Animal
Welfare and Ethical Review Body of Imperial College
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London. The number of mice for each experiment is
given in Additional file 2.
Husbandry, genotyping and CAG repeat sizing
Hemizygous R6/1 mice were purchased from Jax
Laboratories and bred by backcrossing R6/1 males to
(CBA x C57BL/6) F1 females (B6CBAF1/OlaHsd, Charles
River, UK). Genomic DNA was isolated from a tail tip. R6/
1 mice were genotyped by PCR and the CAG repeat was
measured by sequencing as previously described [27].
Production of rAAV
rAAV2/1-GFP, rAAV2/1–ZF–KOX1 and rAAV2/1–mZF–
KRAB, containing a pCAG promoter (CMV early enhan-
cer element and the chicken β-actin promoter) and
Woodchuck hepatitis virus postranscriptional regulatory
element (WPRE) [28], were produced at the Centre for
Animal Biotechnology and Gene Therapy of the
Universitat Autonoma of Barcelona, as described previ-
ously [14]. Recombinant virus was purified by precipitation
with PEG 8000, followed by iodixanol gradient ultracentri-
fugation with final titers of ~1012 genome copies/mL.
rAAV2/1–pNSE-mZF–KRAB-WPRE and rAAV2/9–pHSP-
mZF–KRAB-WPRE were produced in a similar manner.
Stereotaxic surgery
Briefly, mice were anesthetized with a mix of ketamine
(75 mg/kg) and medetomidine (1 mg/kg, i.p.) or isoflur-
ane (preferred) and fixed on a stereotaxic frame.
Analgesia was provided by buprenorphine (8 μg/kg, s.c.).
AAVs were injected unilaterally into the striatum (A/P
+0.7 mm, M/L ± 1.8 mm, D/V −2.5 mm, relative to
bregma) using a 10 μl Hamilton syringe at a rate of
0.25 μl/min, controlled by an Ultramicropump (World
Precision Instruments). In all experiments, except where
noted, for each hemisphere we administered 2 × 109
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Fig. 1 Zinc finger (ZF) mouse host-adaptation design and rAAV2/1 transfer into the striatum. a Comparison of the ZF-KOX1 and mZF-KRAB zinc finger
repressor designs, showing the 11-finger constructs aligned to their target poly(CAG) DNA sequence (mut HTT). Protein domains containing non--
mouse peptide sequences (containing potential foreign epitopes) are shaded in red. The sequences of representative DNA recognition helices from
fingers 2 and 3 (F2, F3) are displayed below the ZF arrays, with foreign sequences in red font. The percentage totals of non-mouse residues within the
full length peptide sequences are given to show that the mouse-adapted design reduces overall non-host sequences. Full annotated sequences are
provided in Additional file 1. b Representative specimen showing GFP expression in mouse coronal slices of hemi-brains, from anterior to posterior
view. The anteroposterior (AP) location of each slice within the brain of the mouse is shown as AP distance from Bregma, following [39]. c Bar chart
showing the average volume (±S.E.M) of the whole dorsal striatum and the volume covered by GFP fluorescence. Abbreviations: NLS, nuclear localization
signal; ac, anterior commissure; cc, corpus callosum; DSt, dorsal striatum; LV, lateral ventricle. Scale bar: 1 mm
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genomic particles or sterile PBS. We assume that the ef-
ficiency of transduction is similar in all groups because
infections spread throughout the striata (Fig. 1b, c).
However, we note that different volumes were used to
match viral titre between all samples (3 μl injections for
ZF-KOX; 1.5 μl injections for PBS, GFP and mZF-
KRAB). Mice were killed at 2, 4 or 6 weeks after the in-
jections, for qRT-PCR and histological analyses. To min-
imise animal use, the data at 2 weeks were taken from a
subset of mice from our previous study [14].
Intraventricular AAV injection protocol
Neonatal mice (P0.5) were cryoanesthetized (3 weeks
dataset) or anesthetized with isoflurane (6, 12 and
24 weeks datasets) and subjected to bilateral intraventricu-
lar injection of AAVs, within 24 h of birth to ensure full
ventricular dilation, using a protocol slightly modified
from [29]. The maximum possible volume of 2 μl of viral
vector, or PBS, was injected into each cerebral lateral ven-
tricle, using a sterile Hamilton microsyringe. Thus, we
injected 4 μl in total per mouse, with a viral titre of 2.5 x
109 AAV / μl (1010 viral particles total). Mice were killed
at 3, 6, 12 or 24 weeks after the injections and brains were
harvested, snap frozen in liquid nitrogen, and stored
at −80 C until further analysis by qRT-PCR.
qRT-PCR for 2, 4 and 6 weeks dataset
Mice were humanely killed by cervical dislocation. As
rapidly as possible, they were decapitated and the striata
were dissected on ice and immediately frozen in liquid
nitrogen, for later RNA extraction. RNA was prepared
with RNeasy kit (Qiagen) and reverse transcribed with
Superscript II (Invitrogen). Real Time PCR was per-
formed in a LightCycler® 480 Instrument (Roche) using
LightCycler® 480 SYBR Green I Master (Roche). SYBR
Advantage GC qPCR Premix (Clontech) was used to
amplify the human HTT transgene in R6/2 and R6/1
templates. For technical replicates, each PCR was done
at least in triplicate, and results normalized to three
housekeeping genes (mHprt, mActb and mAtp5m as in
our previous study [14]). At least 3 independent bio-
logical replicates were done for each experiment. Primer
sets are given in full in Additional file 3.
qRT-PCR for 3, 6, 12 and 24 weeks dataset
Total RNA was extracted with the mini-RNA kit accord-
ing to the manufacturer’s instructions (Qiagen). Reverse
transcription (RT) was performed using Superscipt III
reverse transcriptase (Invitrogen) and a mixture of
Oligo-dT and random hexamers (Invitrogen). The final
RT reaction was diluted 10-fold in nuclease-free water
(Sigma) for further qPCR reactions. All Taqman-qPCR
reactions were performed using the LightCycler 480
Real-Time PCR Detector (Roche) as described [27].
Stable housekeeping genes for qPCR profiling were
determined using the Primer Design geNorm™ House-
keeping Gene Selection Mouse Kit with PerfectProbe™
software (Additional file 4). The following housekeeping
genes were identified as suitable for qPCR analysis: B2m,
(Beta-2-microglobulin, 12010), 18S (18S rRNA, 19791),
Eif4A2 (Eukaryotic translation initiation factor 4A2,
13682). Estimation of mRNA copy number was deter-
mined in triplicate for each RNA sample by comparison
to the geometric mean of three endogenous housekeep-
ing genes (Primer Design) as described previously [27].
Primer sets are given in full in Additional file 3.
Immunohistochemistry
Mice were transcardially perfused with PBS followed by
formalin 4 % (v/v). Brains were removed and post-fixed
overnight at 4 °C in formalin 4 % (v/v). Brains were then
cryoprotected in a solution of sucrose 30 % (w/v), at 4 °C,
until they sank. Brains were frozen and sliced with a freez-
ing microtome in 6 parallel coronal series of 40 μm (dis-
tance between slices in each parallel series: 240 μm). We
employed the indirect ABC procedure for the detection of
the neuronal marker Neu-N (1:100, MAB377 Millipore) in
the first series, the reactive astroglial marker GFAP (1:500,
Dako) in the second series and the microglial marker Iba1
(1:1000, Wako) in the third series. Briefly, sections were
blocked with 2 % (v/v) Normal Goat Serum (NGS, Vector
Laboratories) in PBS-Triton100 0.3 % (v/v) and endogen-
ous peroxidases activity blocked with 1 % (v/v) hydrogen
peroxide (H2O2) in PBS for 30 min at room temperature.
Subsequently, sections were incubated for 30 min at room
temperature in (i) primary antibody (at the concentration
indicated above) in PBS with 0.3 % (v/v) Triton X-100 and
2 % (v/v) NGS, (ii) biotinylated secondary antibody in the
same buffer, and (iii) avidin–biotin–peroxidase complex
(ABC Elite kit Vector Laboratories) in PBS-Triton X-100
0.3 % (v/v). Sections were washed 3x10 min in PBS. The
peroxidase activity was revealed with SIGMAFAST-DAB
(3,3′-Diaminobenzidine tetrahydrochloride, Sigma-Aldrich)
in PBS for 5 min. Sections were rinsed and mounted onto
slides, cleared with Histoclear (Fisher Scientific) and cover-
slipped with Eukitt (Fluka). The fourth GFP-injected series
was mounted onto slides and covered with Mowiol (Sigma-
Aldrich) for fluorescence analysis.
Image analysis
Determination of the volume of injection
Five coronal slices per GFP-injected hemisphere from
bregma 1.5-mm levels, separated 240 μm, were photo-
graphed with a digital camera attached to a macrozoom
microscope (Leica). The contours around GFP-
expressing area and dorsal striatum were manually
defined and the area was measured with ImageJ software
(National Institute of Health, USA). Volume was
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calculated as area per distance between slices, according
to the Cavalieri principle [30].
Determination of O.D. for GFAP and IBA1 stainings
Four coronal slices per mouse and hemisphere covering
the striatum from bregma 1.5-mm levels were selected,
and a region of interest of 670 × 897 μm2 in the middle
of dorsal striatum was captured with a 10x objective
using a digital camera attached to a microscope (Leica
DMIRBE). The O.D. of the areas was measured with
ImageJ, the mean density per hemisphere calculated and
O.D. for GFAP and IBA1 of control hemispheres were
subtracted from the injected hemisphere.
Determination of the neuronal density of the striatum
Cell density was calculated using an adaptation of the
unbiased fractionator method [30]. Four coronal slices
per mouse and hemisphere covering the striatum from
bregma 1.5-mm levels were selected, and a region of
interest of 447 × 598 μm2 in the middle of dorsal stri-
atum was captured with a 15x objective using a digital
camera attached to a microscope (Leica DMIRBE). A
grid image leaving 16 squares of 35 × 35 μm2 was super-
imposed to the pictures and a person blinded to sample
treatment counted the number of stained nuclei.
Statistical analysis
Data were analysed StatPlus package for Excel (Micro-
soft) and IBM SPSS Statistics 22. To test the inflamma-
tory response we calculated the difference of O.D. of the
injected hemisphere versus the control hemisphere and
performed a Student’s t test against no difference value
(0). For neuronal density, we performed a paired Stu-
dent’s t test of neuronal density in the injected hemi-
sphere versus the control hemisphere. We analysed the
neuronal density across contralateral hemispheres with
an ANOVA, followed by post-hoc comparisons with the
contralateral hemispheres of the PBS samples. To test
repression, we calculated the percentage of mutant HTT
(mut HTT) or the gene of interest (Htt, Atn1, Atxn2,
Tbp) in the injected brain, with respect to the control
hemisphere, and performed a one sample Student’s t test
against the no repression value (100 %). To ensure a fair
comparison between injected and contralateral hemi-
spheres, only mice with <1 % ZF expression in the
contralateral hemisphere, relative to the injected hemi-
sphere, were used for statistical analyses (see Additional
file 5 for the full dataset). To test the correlation
between RNA levels of the different genes and ZF
expression we applied a linear regression test. To test
expression levels across different times post-injection we
applied a one-way ANOVA. All significance values are
set at p = 0.05.
Results and discussion
Design of the mouse host-matched ZF
Starting with the most effective lead construct from our
previous paper (ZF11xHunt-KOX1 [14]; hereafter named
ZF-KOX1), we designed a mouse host-matched ZF (mZF-
KRAB) to reduce potential immunogenicity (see Additional
file 1, for full annotated sequences). The design modifica-
tions in mZF-KRAB (Fig. 1a) are described more fully in
Methods. Briefly, the changes include removing FLAG
epitope tags and changing effector domains, such as
nuclear localization signals and KRAB repressors, to mouse
analogues. We also altered the zinc finger recognition heli-
ces to make them as close as possible to the mouse zif268
transcription factor sequence [22] (i.e., to reduce the poten-
tial for foreign epitopes). These changes were carried out
within the constraint of retaining CAG-binding activity,
using previous ZF ELISA experiments as a guide [24].
Overall, the original ZF-KOX1 had 260/509 non-
mouse residues (51 %), whereas mZF-KRAB had 66/430
(15 %) (Fig. 1a). We thus reduced the non-wild-type
mouse sequences in mZF-KRAB to a bare minimum,
with all the remaining non-mouse sequences being es-
sential for DNA binding functionality. In order to have a
positive control for the toxicity of a foreign protein in
mice, we chose GFP, which is derived from the jellyfish,
Aequorea victoria. GFP toxicity after AAV delivery to
the brain is well described in the literature [11-13] and
was used as a benchmark to gauge how the ZF con-
structs fared by comparison.
Host-matching reduces the microglial proliferation
observed with ZF-KOX1 and GFP
Microglial cells are the main players in brain innate im-
mune responses, so we tested whether various treat-
ments activated microglia. We performed unilateral
injections of recombinant adeno-associated viral con-
structs (rAAV2/1-ZF-KOX1, rAAV2/1-mZF-KRAB and
rAAV2/1-GFP), or PBS, in the striata of wild-type (WT)
mice (Fig. 1b). WT mice were used to avoid any con-
founding effects of the HD phenotype. To check the infec-
tion region covered by our injection procedure, we
measured the volume covered by GFP fluorescence in
GFP-injected samples (Fig. 1b). This revealed a consistent
average of ~50 % infection, both at 4 and 6 weeks post-
injection (Fig. 1c). No GFP fluorescence was apparent out-
side of the injected striatum. Since the number of viral
copies and the vector amount used was the same for GFP,
ZF-KOX1 and mZF-KRAB, we assume that the efficiency
of transduction is similar in all groups.
To measure microglial upregulation, we carried out
immunostaining with a marker for the ionized calcium-
binding adapter molecule 1 (Iba1). The tissues were then
analysed by quantifying the O.D., following a previously
published procedure [11]. A Student’s t-test, compared
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the O.D. value of the injected hemispheres against the
background O.D. of the contralateral, non-injected
hemisphere (Fig. 2a). This revealed that ZF-KOX1 and
GFP provoked significant increases in microglia, at 4 and
6 weeks post-injection, respectively (c.f. Fig. 3a, f ). For ZF-
KOX1, the average values of O.D. at 6 weeks were similar
to 4 weeks post-injection, but the increased variability in
the samples prevented the result from reaching statistical
significance. As some of these samples showed dense Iba1
+ immunostaining, the conclusion is that ZF-KOX1 treat-
ment results in a sustained inflammation at both 4 and
6 weeks after injection (Fig. 3a, b).
In contrast, mZF-KRAB and PBS injections did not
significantly increase the amount of microglial staining
(Fig. 3c, d, g, h). Only scattered enlarged microglial cells
could be detected in the tissue, mainly surrounding the
needle tract, in both the mZF-KRAB and PBS-injected
hemispheres. Thus, the injection of the foreign proteins,
ZF-KOX1 and GFP, induced a strong proliferation of
microglial cells in WT mice, at different time points,
which was not present in the case of the host-matched
mZF-KRAB.
mZF-KRAB provokes reduced and short-lived astroglial
reactivity, relative to ZF-Kox1 and GFP
We next checked if the treatments provoked an increase
in reactive astroglia by immunostaining the mouse brain
slices for glial fibrillary acidic protein (GFAP), and meas-
uring O.D., as in the previous experiment. We compared
the O.D. value of the injected hemispheres against the
basal O.D. of the contralateral, non-injected hemisphere
by means of a Student’s t-test (Fig. 2b). This revealed
that GFAP was significantly upregulated in the injected
hemispheres, in both time points, in the ZF-KOX1 sam-
ples (Fig. 4a, b). The mZF-KRAB samples showed less
GFAP upregulation, and even this was mainly restricted
to areas surrounding the needle tract (only significant at
4 weeks post injection) (Fig. 4c, d). In contrast, GFP
caused a delayed reactivity, reaching a significant increase
(with respect to the control hemisphere) at 6 weeks post-
injection (Fig. 4f). The PBS control injection did not in-
duce a significant increase in reactive astroglia (Fig. 4g, h).
Isolated, non-reactive astrocytes were found in all contra-
lateral, non-injected hemispheres (Fig. 4). Overall, ZF-
KOX1 and GFP caused a persistent activation of astroglial
cells in WT mice, whereas for mZF-KRAB and PBS this
activation was weaker and was already reduced at week 6
post-injection.
mZF-KRAB is less toxic than ZF-KOX1 or GFP, which both
induce significant neuronal death
To verify whether the observed inflammatory responses
were accompanied by neuronal loss, we used immuno-
histochemical detection of the neuronal marker NeuN.
We first estimated the neuronal density in each hemi-
sphere of the various treated animals (Fig. 5). A Stu-
dent’s t-test between the injected and the non-injected
hemispheres revealed that number of neurons showed a
trend towards reduction by ZF-KOX1 by week 4 after
injection (p = 0.08) (Fig. 5). This reduction reached sig-
nificance by 6 weeks post-injection (p = 0.014). More-
over, for ZF-KOX1, we could observe extensive neuronal
death in some samples after 6 weeks, resulting in no ef-
fective detection of NeuN in the area surrounding the
injection (Fig. 6a, b). In fact, no Neu-N could be ob-
served at all in some of the slices, which displayed only
high background staining.
By contrast, mZF-KRAB did not affect neuronal dens-
ity, either at 4 or 6 weeks after treatment (Fig. 6c, d).
We observed a limited reduction in the number of neu-
rons near the needle tract in two out of four animals at
week 6 post-injection, but the numbers did not reach
significance (p = 0.13). In general, most of the mZF-
KRAB treated samples were similar to PBS injected
hemispheres (Fig. 6g, h).
Finally, in agreement with the previous observations in
Iba1+ and GFAP immunodetection, neuron density was
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Fig. 2 Relative O.D. values of the striatal samples immunostained for
glial markers. Relative O.D values, representing inflammatory responses to
various treatments, were calculated for the microglial marker IBA1 (a)
and the reactive astroglial marker GFAP (b), at 4 and 6 weeks after
injection. Unoptimized ZF-KOX1 treatment was compared to expression
of a host optimized mZF-KRAB, GFP or a control PBS injection. Relative
O.D. is calculated as the mean O.D. of four coronal slices, separated by
240 μm in the injected hemisphere, minus the average O.D. in the
contralateral control hemisphere. Data are displayed as Relative
O.D. ± S.E.M, *** P < 0.001, **P < 0.01, *P < 0.05
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not affected by GFP at 4 weeks post-treatment (Figs. 5,
6e), with only some areas showing scarcely-distributed
neurons close to the needle tract. However, GFP signifi-
cantly reduced neuronal density by week 6 post-
injection (p = 0.018). The cytotoxicity of GFP was thus
observed after a delay and was the strongest toxic effect
observed in this study.
ZF-KOX1 represses the mut HTT polyCAG target in vivo
for up to 6 weeks
In previous work, we had determined that ZF-KOX1
functionally repressed its target in R6/2 HD model mice
for 2-3 weeks after bilateral injection, during which time
pathological clasping symptoms were virtually abolished
[14]. We now explored whether repression was sustained
for a longer period, up to 6 weeks. We therefore injected
rAAV2/1-ZF-KOX1 into R6/2 mice only in one hemi-
sphere and left the contralateral hemisphere uninjected,
for baseline comparison. Taking samples 2, 4 and 6 weeks
after injection, we analysed RNA levels via quantitative
real-time PCR [14] (Fig. 7a).
To verify whether ZF-KOX1 was able to repress its
target gene (mut HTT) in a dose-dependent manner, we
carried out linear regression of the RNA levels of mut
HTT versus ZF-KOX1, for each time point (Fig. 7a). There
was a significant and negative correlation between these
RNA levels 2 weeks after treatment (p = 0.04). There were
also trends approaching significance at 4 and 6 weeks
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Fig. 3 Microglial activation in the striatum after various treatments. Representative micrographs of IBA1 immunostained striatal coronal slices, for the
control and injected hemispheres, for each treatment at 4 or 6 weeks. ZF-KOX1 samples displayed an apparent increase in Iba1 immunoreactivity in
the injected hemispheres, at 4 and 6 weeks after treatment (a, b). This was not observed in the contralateral hemispheres (a’, b’). Hemispheres treated
with mZF-KRAB showed similar levels of Iba1+ cells compared with their contralateral non-injected hemispheres (c, c’, d, d’). Certain GFP-treated
samples showed a slight increase in Iba1 immunoreactivity 4 weeks after treatment (e). Iba1 immunoreactivity was significantly increased 6 weeks after
GFP injections, compared with the contralateral hemispheres (f, f’). PBS-injected samples show similar Iba1 immunoreactivity between hemispheres at
both time points (g, g’, h, h’). Scale bar: 100 μm
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(p = 0.05, p = 0.09). These results indicate that, although
there is variability in individual injected mice, higher ex-
pression of the ZF-KOX1 results in lower levels of mut
HTT, which is consistent with previous results [14].
By comparing the mut HTT levels in the ZF-KOX1-
injected hemisphere to the baseline in the uninjected
hemisphere (Fig. 7b), we observed that ZF-KOX1 yielded
a mean reduction in mut HTT of ~35 % after 2 weeks,
which is in the therapeutic range [14]. Repression was
maintained at ~20 % at 4 and 6 weeks after injection
(Fig. 7b). However, ZF-KOX1 expression was accompan-
ied by a significant cell loss (Figs. 5, 6). For this reason,
we decided that ZF-KOX1 should not be used for any
further experiments in mice and we did not extend this
trial.
mZF-KRAB represses the mut HTT polyCAG target in vivo
We next explored whether host-matched mZF-KRAB
was a more suitable candidate for long-term repression
of mutant huntingtin (mut HTT). The early-onset R6/2
phenotype is useful for phenotyping trials but, as a result
of Ethical Review (see Methods), we refined the proced-
ure for collecting ZF expression and repression data at
6 weeks, and switched to the later-onset HD mouse
model, R6/1. Ethically, the use of R6/1 is preferred over
R6/2 because the data can be collected before any HD
symptoms are detected, maximising animal welfare. In
fact, both R6/1 and R6/2 bear the same transgene, al-
though the CAG repeats are slightly longer in the R6/2
mice we are using (~160 repeats versus ~120-130 in R6/
1). This repeat number difference should not matter for
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Fig. 4 Astroglial activation in the striatum and cortex after various treatments. Representative micrographs of GFAP immunostained striatal coronal
slices for the control and injected hemispheres, for each treatment at each time point. ZF-KOX1 samples displayed a strong and sustained increase in
GFAP immunoreactivity in the injected hemispheres, 4 and 6 weeks after treatment (a, b). In contrast, mZF-KRAB treatment provoked a transient
upregulation of GFAP immunoreactivity, which started to decline at 6 weeks post-injection (c, d). GFAP immunoreactivity after GFP injections followed
the pattern of Iba1 staining, with a slight increase 4 weeks post-treatment and significant signal increase at 6 weeks post-treatment (e, f). Isolated, non-
reactive astrocytes can be observed at PBS-injected samples and their contralateral hemispheres (a’, b’, c’, d’, e’, d’, g, g’, h, h’). Scale bar: 100 μm
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quantifying repression, since we see comparable ZF re-
pression in StHdh cells with 111 repeats [14]. Although
R6/1 is thus a valid model for testing zinc finger repres-
sion, the repression data should not be formally com-
pared to the results with R6/2, because of the different
time-dependence of the HD phenotypes.
We injected rAAV2/1-mZF-KRAB into R6/1 mice and
killed them at 2, 4, and 6 weeks post-injection, taking
samples to analyse RNA levels via quantitative real-time
PCR. mZF-KRAB RNA levels were negatively correlated
with mut HTT at 2 and 4 weeks post-injection (p < 0.05)
(Fig. 7c). This indicates that mZF-KRAB target repres-
sion is functioning. The linear correlation was lost by
week 6 post-injection, although the majority of mice still
had reduced mut HTT levels in the injected hemisphere,
with respect to control levels. Interestingly, studies in
mice have shown that transient repression of mut HTT
with modified oligonucleotides can persist for 8 weeks
after the treatment [17]. Therefore, it is likely that we
are observing persistent repression of mut HTT at
6 weeks, which is no longer correlated to mZF-KRAB
expression because of a trend towards a reduction in
ZF expression over time, under the pCAG promoter
[31]. It should be noted that KRAB domains lay down
heterochromatin across genetic loci and thus cause
strong long-term repression which can outlast their
expression [21].
By comparing the mut HTT levels in the mZF-KRAB-
injected hemisphere to the baseline in the uninjected
hemisphere (Fig. 7d), we saw that repression was on
average ~30 % at 2 weeks (p = 0.04) and stabilised
around ~20 % at 4 and 6 weeks (p = 0.04, p = 0.05,
respectively). Thus, mZF-KRAB is functionally active in
repressing mut HTT at 6 weeks and this, together with
its reduced apparent toxicity, makes this construct
suitable for in vivo use.
mZF-KRAB specifically represses mut HTT and not other
CAG-containing genes
Since the mouse genome contains 7 potential polyQ ex-
pansion genes [14], we checked whether the transcriptional
repression of mut HTT was specific or whether it affected
some of these other polyCAG-targets. We tested the ef-
fects of ZF-KOX1 and mZF-KRAB on the expression of
four of these genes (wild-type WT Htt, Atn1, Atxn2, Tbp;
Table 1). The results show that the RNA levels of these
genes were not negatively correlated with ZF expression,
except, strikingly, in the case of WT Htt with ZF-KOX1, at
all time points (Table 1). In particular, ZF-KOX1 signifi-
cantly repressed ~10 % of mouse WT Htt, 2 and 4 weeks
after treatment, in a dose-dependent manner (Table 1).
Conversely, none of the gene expressions were correlated
with mZF-KRAB at any point. Thus, at least under the
conditions tested, mZF-KRAB appears to be specific
against its target, which may also be contributing to its low
apparent toxicity.
A non-viral promoter for long-term ZF expression and
functional mut HTT repression
Up to this point, the ZFs used in this study had been
expressed from a very strong pCAG promoter (CMV
early enhancer element and chicken β-actin promoter)
with the Woodchuck hepatitis virus postranscriptional
regulatory element (WPRE). Although this construct
achieved strong repression of mut HTT, there was a
trend to loss of transgene expression over 6 weeks. Since
this was not attributable to cell loss in the case of mZF-
KRAB, it was possible that promoter silencing was
occurring. Indeed, it has been found that the pCAG pro-
moter is methylated and may lose transgene expression
over time [31]. Consequently, we explored whether a
non-viral promoter might be better for maintaining
transgene expression.
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As an alternative to pCAG, we selected the 1.8 kb rat
neuron specific enolase promoter (pNSE), because this
was shown to give persistent expression that is several
100-fold greater than the short CMV promoter in rodent
brains [32, 33]. In combination with a WPRE, pNSE gave
strong stable luciferase expression in the rat striatum,
even at 15 months post injection [34].
The pNSE promoter was synthesized chemically and
vectorised to express mZF-KRAB-WPRE, using rAAV2/
1. To set up long term ZF expression and mutant HTT
repression experiments, we carried out bilateral intra-
ventricular injection on neonatal R6/1 and WT mice,
with the maximum volume of AAV possible (4 μl, ~1010
virions). Whole brains were harvested after 3, 6, 12 and
24 weeks and analysed by qPCR to determine ZF
expression and mutant HTT repression, while PBS and
the previous pCAG promoter construct were used as
controls. We found that whereas pCAG promoter activ-
ity was lost by 6 weeks, the pNSE promoters had rela-
tively stable expression up to 12 weeks (74-78 % of
maximum) and ZF was still detectable after 24 weeks (4-
5 % of maximum pNSE levels and 10-12 % of maximum
pCAG levels in WT and R6/1) (Fig. 8a). It should be
noted that the detection of ZF is on a relative scale
and that even ~5-10 % of maximum may still indicate an
absolute concentration of ZF that is still functionally ac-
tive; this can only be determined by examining the repres-
sion of target mutant HTT (Fig. 8b).
When looking at repression of mutant HTT, pCAG-
driven repression was only detected at 3 weeks and was
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Fig. 6 Visualising striatal neuronal density after various treatments. Representative micrographs of Neu-N immunostained striatal coronal slices for
the control and injected hemisphere of each treatment at each time point. ZF-KOX1 toxicity is observed in areas of the injected striata that are
devoid of marked neurons, 4 and 6 weeks after treatment (a, b), whereas the contralateral hemispheres (a’, b’) show neuronal densities similar to
PBS injected (g, h) and untreated hemispheres (g’, h’). Conversely, mZF-KRAB treatment did not significantly affect neuronal density (c, c’, d, d’).
Strikingly, GFP injections did not affect neuronal density at 4 weeks after treatment (e, e’), but caused a delayed strong toxic response that
reduced neuronal density both in the injected (f) and the contralateral hemisphere (f’), 6 weeks post-injection. Scale bar: 100 μm
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lost by 6 weeks (Fig. 8b), matching the complete loss of
detectable ZF expression from this promoter. By con-
trast, pNSE-driven repression was maintained over the
entire 24-week period, albeit with a trend to reduction
over time (Fig. 8b). At 3, 6, 12 and 24 weeks, respect-
ively, this resulted in 77 %, 61 %, 48 % and 23 % repres-
sion of mutant HTT in whole brain samples. Notably,
pNSE-ZF still repressed mutant HTT levels by nearly a
quarter after 24 weeks, which is close to levels previously
found to be in the therapeutic range (Fig. 6a of Ref.
[14]). As expected, the short WT Htt allele was
unaffected in all samples, indicating a lack of off-target
activity (Fig. 8c). Overall, the results show that combin-
ing our host-adapted mZF-KRAB design with the pNSE
promoter allows targeted mut HTT repression in the
whole brain, for an extended 6 month period that is
much longer than the 3 weeks reported previously [14].
Conclusions
The humanization of biologics, such as engineered anti-
bodies, is long established as a way of reducing immuno-
reactivity in therapy [35, 36]. Adapting synthetic gene
therapy constructs for their hosts is relatively more chal-
lenging because they can have more components, and
longer functional regions have to be considered. For
example, multiple zinc finger binding helices usually re-
quire several non-wild-type amino acids to bind desired
target sequences (Fig. 1a). Nonetheless, these differences
can and should be minimized.
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Fig. 7 Mutant huntingtin gene expression analysis after treatment with ZFs. a Linear regression showing negative correlations of mut HTT RNA levels and
ZF-KOX1 expression 2, 4, and 6 weeks after treatment, suggesting an effective repression of mut HTT by the treatment. Black diamonds show the mean
mut HTT expression values (±1 S.E.M.) of the control hemispheres of each group. ZF-KOX1 expression levels are in arbitrary units (a.u), normalised to the
maximum ZF-KOX1 qRT-PCR signal across all samples. b Percentage of mut HTT with respect to the average value in the control hemispheres, over the
same period. The data show an average of ~25 % reduction of mut HTT, 2 weeks post-treatment (previously reported in [14]), with an individual mouse
showing up to ~40 % reduction. The average percentage increases with time, but later values should be interpreted cautiously because of ZF-KOX1
expression leakage to the contralateral hemisphere, and because of the significant neuronal loss. c Linear regression analysis testing for
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The first aim of this study was to replace all effector
domains with host homologs and to reengineer the func-
tional DNA-binding domain to retain its designed activ-
ity. The latter required using the fewest possible amino
acid changes, relative to the host organism protein scaf-
fold (in this case, the mouse zinc finger domain, Zif268).
The design changes we introduced were sufficient to
reduce neuronal cell loss, making the gene therapy con-
struct less toxic than even a GFP expression vector; in
fact, the mouse host-adapted construct behaved more
like a control PBS injection.
The reduction of inflammatory responses following
host-matching of the ZF construct suggests an immune
response against non-self proteins as the most likely ex-
planation for the detected medium-term toxicity. How-
ever, when host-matching, we made several changes,
including differences in the NLS, ZF DNA-binding heli-
ces, and KRAB repressor domain. It is therefore possible
that certain individual elements contribute to reduced
immunogenicity or toxicity, rather than broad host-
matching; without further testing it is difficult to extend
the conclusions outside of this system and future work
is needed to establish whether such host-matching is a
generic strategy. Furthermore, although the host-
matching changes aimed at conserving function (i.e.,
DNA binding to poly-CAG and KRAB repression), it is
possible that these changes introduced subtle differences
which contributed to lower toxicity. For example, al-
though the mouse KRAB domain was chosen to have
similar transrepressing activity to KOX1 [23], it may
have had altered activity which resulted in lower off-
target effects. Similarly, mZF-KRAB was more specific
against off-target short poly-CAG genes (Table 1), which
may also have contributed to its apparent lower toxicity.
Arguing against this is our previous observation of the
lack of apparent toxicity of ZF-KOX1, both in cell cul-
ture and in short term in vivo assays. Indeed, we were
able to generate stable cell lines expressing ZF-KOX1 in
vitro, and a cell viability assay showed no toxic effects
[14]. Therefore the strong inflammatory responses seen
with ZF-KOX1, which were absent with mZF-KRAB, re-
main a likely reason behind the improved tolerance of
the latter in vivo.
The apparent success of mouse host-adaptation raises
the question of what construct should be made for an
eventual human therapy. Based on the results presented
here, we would suggest that the effector domains (i.e.,
NLS, zinc finger scaffold, KRAB domain) should all be
human. The engineered changes required for function
(e.g., ZF linkers, ZF DNA recognition helices) should all
be kept to a minimum and should be as close as possible
to the corresponding human scaffold sequences. In
principle, epitope scanning [37] can also help to guide
the final choice of amino acid design changes, with the
aim being to reduce potential epitopes in the remaining
non-human regions.
The second aim of this study was to explore whether
the loss of activity of the pCAG promoter could be
bypassed by using a non-viral promoter-enhancer, and
whether this would maintain measurable levels of mut
HTT repression in whole brain. Endogenous promoters
have been developed for gene therapy [38] but, to our
knowledge, no-one has tested a promoter for long-term
expression of a transgene transcription factor. Our results
show that the 1.8 kb rat neuron specific enolase Eno2 pro-
moter (pNSE [34]) is active for this purpose in the whole
brain. Although maximal mutant HTT repression of 77 %
was observed after 3 weeks, 23 % repression was still ob-
served after ~6 months, which is a striking improvement
upon previous pCAG (CMV-enhanced) constructs.
Despite these improvements, we still observed a slow
reduction in ZF expression over time with our final con-
struct, rAAV2/1:pNSE-mZF-KRAB-WPRE. The cause is
not immediately apparent, and there appears to be a
drop between 12 and 24 weeks (expression is relatively
stable between 6 and 12 weeks; Fig. 8a). Promoter shut-
down and cell loss are possibilities, although the former
goes against previous reports [34], and the latter is
unlikely because it would likely be accompanied with a
severe phenotype, which we did not observe. An
Table 1 Expression of mouse endogenous CAG-containing genes after treatment with ZF-KOX1 and mZF-KRAB
Treatment Weeks
post-injection
Linear
regression
Htt (4,7) % Linear
regression
Atn1
(3,10) %
Linear
regression
Atxn2
(6,10) %
Linear
regression
Tbp
(3,13) %
ZF-KOX1 2 R2 = 0.97§ 92.1 ± 0.4* R2 = 0.03 101.2 ± 13.8 R2 = 0.09 95.5 ± 3.9 R2 = 0.98§ 94.5 ± 5.0
4 R2 = 0.99§ 89.6 ± 2.4* R2 = 0.64 91.7 ± 13.7 R2 = 0.57 96.1 ± 6.8 R2 = 0.98 91.5 ± 1.7
6 R2 = 0.99* 90.6 ± 9.6 R2 = 0.09 106.3 ± 4.9 R2 = 0.96 98.4 ± 2.9 R2 = 0.65 98.1 ± 3.3
mZF-KRAB 2 R2 = 0.53 98.3 ± 3.3 R2 = 0.02 109.4 ± 10.6 R2 = 0.00 103.3 ± 11.8 R2 = 0.08 99.1 ± 7.9
4 R2 = 0.14 88.4 ± 6.7 R2 = 0.19 88.6 ± 7.3 R2 = 0.36 89.6 ± 5.4 R2 = 0.43 90.5 ± 10.4
6 R2 = 0.43 92.5 ± 11.35 R2 = 0.16 91.4 ± 6.5 R2 = 0.00 96.7 ± 4.4 R2 = 0.07 94.7 ± 4.8
The first number (in brackets after the name of the gene) represents the number of CAG repeats, the second the number of glutamines in the coding stretch
(CAG + CAA). Values are given as the percentage expression of the gene of interest, with respect to the average values in the control hemispheres. The result of
ZF-KOX1, 6 weeks post-injection, should be taken with caution, since at this time point there was a significant neuronal loss and leakage of the vector to the
contralateral hemisphere. In bold: §P < 0.1; *P < 0.05. Atn1: atrophin 1; Atxn2: ataxin 2; Htt: huntingtin (mouse); Tbp: TATA binding protein
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alternative is that viral copy number per cell is reduced
over time: the mice are still growing over this period and
it is possible that we are seeing a dilution of the non-
replicative AAV vector as cells divide. If this is true, then
expression might be maintained from those cells that re-
ceived a higher initial dose. It should be noted that in
the final experiments (Fig. 8) we have used larger AAV
doses than were previously possible (because of previous
limitations in viral titre). With these doses, we have ob-
served the largest TF repression effect seen thus far (up
to 77 % in whole brain). In the future, by using even
more concentrated viral preparations, it may be possible
to increase the AAV dose-per-cell, and the percentage of
the brain that is infected, thus potentially increasing
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Fig. 8 Long-term effects of bilateral intraventricular injection of AAV expressing mZF-KRAB under pCAG or pNSE promoters. a Zinc finger expression
over time. mZF-KRAB transcript levels from whole brains were assayed by qRT-PCR at 3, 6, 12 and 24 weeks after viral (or PBS control) injections, in WT
or R6/1 neonates. b Zinc finger repression of mutant Huntingtin in R6/1 mice. mut HTT (exon 1) expression levels in the whole brain samples from the
various treatments were compared to transcript levels in PBS controls, by qRT-PCR. c Verification of lack of cross-reactivity of mZF-KRAB with short WT
Htt alleles. WT Htt (exon 1) expression levels were quantified in the same treatment samples as above. Housekeeping genes and other control data are
shown in Additional file 5. Error bars are S.E.M (n = 3). ** p < 0.01, *** p < 0.001, n.s. = not significant
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both the treatment effect and period. Nonetheless, the
current results - showing that we have reduced mutant
Huntingtin levels by around a quarter in the whole brain
after six months - demonstrate that we have achieved
our main goal of long term repression.
Overall, developing constructs that function in the
long term is an important aim of gene therapy and the
combination of host optimization and the use of a non-
viral promoter in this study is a major step forward.
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